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ABSTRACT
Severe anaesthetic anaphylaxis is relatively 
uncommon. Oxygen, fluids and epinephrine are 
considered to be the mainstay for treatment of 
cardiovascular collapse and current guidelines 
for the management of anaphylaxis list only 
epinephrine as a vasopressor to use in the event 
of a cardiovascular collapse. Recently, evidence 
has emerged in the support of the use of 
vasopressin in cardiopulmonary resuscitation; 
it is also recommended for the treatment of 
ventricular fibrillation, septic shock and post- 
cardiopulmonary bypass distribution shock. 
Currently, there is no algorithm or guideline 
for the management of anaphylaxis that include 
the use of vasopressin. We report a 24-year-
old woman who developed severe anaphylactic 
shock at induction of anaesthesia while under-
going laparoscopic cholecystectomy. Circulation 
shock was refractory to epinephrine and high 
doses of pure alpha-agonist phenylephrine and 
norepinephrine. Single intravenous dose of 
two units of vasopressin re-established normal 
circulation and blood pressure.
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INTRODUCTION
Anaphylaxis during induction of anaesthesia is 
uncommon. The effects of this complication range from 
mild urticaria to life-threatening circulatory shock. The 
incidence of anaphylaxis and anaphylactoid reactions 
during anaesthesia are probably under-reported and are 
difficult to predict, but have been estimated to range 
from one in 3,500 to one in 13,000 cases.(1,2) Life-
threatening reactions to various anaesthetic drugs have 
been reported in the literature. Muscle relaxants (69%) 
and natural rubber latex (12%) are the most frequently-
reported agents to cause anaphylaxis. Other causes 
include drugs, such as antibiotics (8%) and induction 
agents (4%).(3-5) Successful management of anaphylaxis 
depends on prompt diagnosis and appropriate 
management. We report a case of anaphylaxis that 
was resistant to catecholamine vasoconstrictors 
(epinephrine, norepinephrine and phenylephrine) but 
responded to vasopressin.
CASE REPORT
A 24-year-old ASA grade 1 woman weighing 74 kg was 
scheduled for elective laparoscopic cholecystectomy. 
She had no known allergies and had undergone an 
uneventful caesarean section under subarachnoid 
block two months previously, during which propofol 
100 mg was used for sedation. The patient was 
premedicated with tablet midazolam 7.5 mg one hour 
prior to surgery. On arrival in the operating room, 
the baseline noninvasive blood pressure was 128/72 
mmHg, heart rate 78/min and oxygen saturation (SpO2) 
100% on room air. General anaesthesia was planned 
for laparoscopic cholecystectomy and coinduction 
was done with fentanyl 100 μg, propofol 100 mg 
and atracurium 30 mg given intravenously following 
pre-oxygenation. Immediately after administration of 
the induction drugs, cyanosis was noticed and SpO2 
suddenly dropped to 80%, as read by pulse oximeter. 
Because of severe hypotension, the pulse waveform 
was not displayed properly. Her blood pressure 
became unrecordable and there was marked reduction 
in end-tidal carbon dioxide concentration. Heart rate 
increased to 140/min and electrocardiography rhythm 
appeared normal. Although the blood pressure was 
not recordable, the femoral and carotid pulses were 
palpable; therefore, chest compressions were not 
started.  
 Her trachea was intubated and ventilation started 
with 100% oxygen, but SpO2 did not improve.  Lung 
auscultation was done to confirm tracheal tube position 
which revealed mild wheezing. No crepitations were 
present. A “call for help” was initiated. Wheezing 
resolved within minutes without any pharmacological 
intervention. There was no clinical evidence of 
pulmonary aspiration, no fluid was encountered in 
the pharynx and a later chest radiograph showed clear 
lungs. Although her heart rate dropped to 58/min, it 
responded to a single dose of intravenous 1 mg atropine, 
but blood pressure was still not recordable. Atropine 
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was used as it was immediately available. Although 
there was no cutaneous rash, a provisional diagnosis 
of an anaphylactic reaction was made and resuscitation 
started. During resuscitation, radial arterial line and 
central venous access through the internal jugular 
vein were secured and confirmed by good waveform 
pattern. Arterial line showed blood pressure of 40/30 
mmHg, and central venous cannulation showed central 
venous pressure of 3 mmHg.  
 Multiple boluses of 100 μg epinephrine (total 
2,000 μg) were given. Since the patient had tachycardia 
(120/min), small bolus doses of epinephrine were 
used. The rationale was that with tachycardia, there is 
a great risk of arrhythmias, which may in themselves 
be fatal in a shocked patient. When the patient did not 
respond to epinephrine boluses, phenylephrine boluses 
100–200 μg (total 4,000 μg) were given. Infusions 
of epinephrine and norepinephrine were started at 
0.03 μg kg-1 min-1 and increased to 0.5 μg kg-1min-1. 
During the resuscitation effort, hydrocortisone 200 mg 
was also administered. We then repeated high bolus 
doses of phenylephrine to restore perfusion and avoid 
further increase in heart rate. Phenylephrine was again 
given in 5 mg boluses (total 20 mg). Resuscitation 
also included infusion of crystalloids and colloids to 
maintain the central venous pressure to 10 mmHg. 
Total resuscitation fluid given was 3,500 ml (1,500 ml 
of gelofusine, i.e. colloid, and 2,000 ml of Ringer’s 
lactate). 
 During 40 min of resuscitative measures, heart 
rate varied from 120 to 130/min, but the blood pressure 
did not rise (systolic varied from 40 to 50 mmHg and 
diastolic 20 to 30 mmHg) and cyanosis was persistent 
(SpO2 of 80%–84%). Arterial blood gases showed 
mixed metabolic and respiratory acidosis (pH 7.20; 
PaCO2 50 mmHg; PO2 68 mmHg; HCO3 11, and 
base deficit -14). Decision was made to add a bolus 
of non-adrenergic vasopressor, vasopressin. 2 units 
of vasopressin were then given intravenously, which 
resulted in a profound response, and blood pressure 
increased to 90/50 mmHg and SpO2 improved to 90%. 
 At this point, the patient started breathing 
spontaneously. Midazolam was given to prevent 
awareness and vecuronium for muscle relaxation. The 
decision was made to postpone the surgery. Infusions 
of epinephrine and norepinephrine were continued. 
She was mechanically ventilated in the operating room 
for an additional hour until her blood pressure was 
stabilised to 100/60 mmHg, SpO2 remained at 97% and 
pH returned to normal, as seen on arterial blood gases. 
Gradually, inotropic support was withdrawn over two 
hours. She was extubated when she required minimal 
inotropic support to maintain her vital parameters and 
SpO2. She made good recovery without any apparent 
memory loss and was able to recognise her family. 
She was kept under observation for 24 hours in the 
postanaesthetic care unit, and was then discharged. 
 The patient was followed-up in the surgical clinic 
for two months for her primary pathology, and with 
the primary anaesthetist for any post-resuscitation 
residual damage and future anesthesia plan. No formal 
psychological evaluation was done, but during these 
visits, she actively participated in the discussion. She 
was an architect by profession and was able to continue 
working. Two months later, she was again scheduled 
for the same surgery under general anaesthesia which 
was uneventful. On this occasion, pre-induction 
intravenous tramadol 150 mg was given and induction 
was done with an inhalation agent (sevoflurane and 
nitrous oxide in oxygen) along with intravenous 
midazolam 5 mg. Vecuronium was used as muscle 
relaxant to facilitate tracheal intubation.
DISCUSSION
Anaphylaxis must be considered as a differential 
diagnosis for any acute-onset respiratory distress, 
bronchospasm, hypotension or cardiac arrest during 
anaesthesia. We suspected anaphylaxis in our case on 
a high index of suspicion. In a healthy 24-year-old 
subject with no other disease and who unexpectedly 
collapsed after the administration of anaesthetic 
induction drugs, the two differential diagnoses would 
be an allergic reaction or aspiration.  Myocardial 
infraction was highly unlikely. At the time of tracheal 
intubation, no residual fluid or blood was encountered 
in the pharynx. Bronchospasm was not the dominant 
presenting feature and the chest radiograph done on 
the operating room table did not show any evidence of 
aspiration. On the other hand, all the induction agents 
used had the possibility of histamine release and cause 
various degrees of anaphylaxis. During an episode of 
suspected anaphylaxis, a confirmation of the diagnosis 
should be sought by an increase in blood histamine 
and tryptase concentrations, indicating a mast-cell-
mediated process.(6) We did not have the facilities to do 
blood histamine and tryptase levels in our laboratory. 
The option of intradermal skin and prick tests for 
induction drugs was given to the patient during the 
follow-up period. When the procedure was explained 
with the advantages, disadvantages and possible 
complications, the patient refused to undergo testing. 
Therefore, she was not referred to an allergist.
 It is not possible to state with confidence as to 
which anaesthetic drug had caused the anaphylactic 
reaction, and the possibility of either propofol, 
atracurium or fentanyl being the causative agent could 
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not be completely eliminated. When we inquired post-
event, the patient had received propofol 100 mg for 
sedation two months ago in a previous anaesthesia. 
It is known that re-exposure to causative agents can 
cause a severe anaphylactic reaction. Points against 
propofol would be that the patient did not encounter 
any complication when she was given propofol the 
first time, as even a first exposure can cause a life-
threatening reaction. Possibility of atracurium causing 
anaphylaxis also could not be ruled out as this is one of 
the most common agents which can cause anaphylaxis 
during anaesthesia (50%–70%). Anaphylaxis to a 
muscle relaxant has also been observed in patients 
with no previous administration. There was absence 
of bronchospasm and skin rashes in our case, but the 
possibility of atracurim causing the anaphylaxis still 
remained high as cardiovascular collapse is a common 
finding of anaphylaxis under anaesthesia without 
bronchospasm and skin changes. Fentanyl could also 
cause an anaphylactic reaction,(7) but there are few 
published case reports to support this.  As no definite 
causative agents could be ruled out we avoided all 
three drugs when she was anaesthetised two months 
after this reaction. 
 Pathophysiological effects of anaphylaxis result 
from immune-mediated release of mediators including 
histamines, prostanoids, leukotrienes, kinins and 
platelet-activating factors. The predominant reasons 
for acute cardiovascular collapse in anaphylaxis are 
mediator-induced vasodilation and leakage of plasma 
from capillaries due to increased permeability.(2) Aims 
in the management of anaphylaxis should be an early 
return of spontaneous circulation, and maintenance 
of adequate coronary and cerebral perfusion. 
Immediate discontinuation of the offending drug, 
airway maintenance, 100% oxygen administration, 
intravascular volume expansion and epinephrine, are 
essential to treat the hypotension and hypoxia that 
result from vasodilatation, increased permeability and 
bronchospasm.(1,8) 
 Epinephrine is a catecholamine with both α- 
and β-adrenergic effects and remains an empirical 
agent in the treatment of anaphylaxis. It opposes 
the deleterious systemic adverse effect of released 
mediators through its vasoconstriction (α-mediated), 
positive inotropic (β1-mediated) and bronchodilating 
(β2-mediated) properties. It also reduces mast cell and 
basophil mediator releases. When an intravenous route 
is available, titrated bolus administration according to 
arterial pressure and pulse is advised (10–20 μg in Grade 
II reaction, 100–200 μg in Grade III reaction, and for 
Grade IV reaction, i.e. cardiac arrest, 1 mg epinephrine 
boluses along with external cardiac massage are 
recommended). Continuous infusion may be required 
in some cases and titrated as needed.(6) Most episodes 
of anaphylaxis respond to treatment with a single 
dose of epinephrine, but anaphylactic cardiovascular 
collapse can be resistant to treatment with this drug, as 
seen in our case.(9) Heytman and Rainbird reported two 
cases in which return of spontaneous circulation was 
refractory to epinephrine.(2) Waldhausen et al reported 
49 patients with anaphylaxis who did not respond 
adequately to epinephrine.(10) Konarzewski and De’Ath 
reported an anaphylactic reaction which was treated 
with standard cardiopulmonary resuscitation (CPR) 
including cardiac massage, ventilation of the lungs 
with 100% oxygen, atropine 3 mg and epinephrine 
2 mg. Despite vigorous resuscitation attempts for 
45 min, the patient died.(11) Similarly, in our patient, 
volume expansion and epinephrine were ineffective.
 It has been reported that early use of alpha-
agonists, along with the second dose of epinephrine, 
may reduce the morbidity and mortality associated 
with anaphylaxis and reduced unwanted sideeffects 
produced by high dose epinephrine.(12) This was first 
described by Higgins and Gayatri.(13) Heytman and 
Rainbird reported beneficial effects of alpha-agonist 
metaraminol in epinephrine-resistant anaphylactic 
shock.(2)  McBrien et al also reported a good response 
to methoxamine in two anaphylactic reactions 
(succinylcholine, cefamandole) and one cardiovascular 
collapse (secondary to methylmethacrylate cement).(14) 
Phenylephirine 10 mg in bolus doses and nor epinephrine 
infusions during open heart surgery have been reported 
successful in the treatment of anaphylaxis.(15) Bolus 
doses of phenylephrine and metaraminol are used in 
various case reports to manage anaphylactic shock. 
As phenylephrine is easily available at our institution, 
we used it for bolus doses along with infusion of 
norepinephrine and epinephrine. We started with 
minimum doses of 100–200 μg. We were reluctant to 
use high doses of epinephrine for fear of ventricular 
arrhythmias in the presence of tachycardia. In this 
case, as it was an emergency situation, we tried large 
bolus doses of phenylephrine, but our patient did not 
respond to norepinephrine infusion at an increasing 
dosage nor to phenylephrine boluses. This was similar 
to the case reported by William et al where hypotension 
was refractory to high doses of phenylephrine.(16)
 Currently, trials to evaluate the effects of 
vasopressin in cardiac arrest, septic shock and 
uncontrolled haemorrhagic shock are being 
performed.(17) Role of vasopressin in cardiovascular 
haemostasis is through its non-adrenergic peripheral 
vasoconstriction (by direct stimulation of smooth 
muscle vasopressin 1 receptors) and antidiuretic 
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action. It produces vasoconstriction in the skin, 
skeletal muscle, intestine and fat, with relatively less 
constriction of coronary and renal vasculature, and 
causes cerebral vasodilatation.(15) Recent evidence 
has emerged for the use of vasopressin in CPR. 
Epinephrine and other catecholamines lose much 
of their effectiveness as vasopressors in a hypoxic, 
acidotic milieu, and this fact has stimulated efforts 
to identify an effective alternative to epinephrine 
for use in this situation. In early 1990s, endogenous 
vasopressin levels were found to be higher in survivors 
of cardiac arrest than in patients who died, suggesting 
that vasopressin could be beneficial in cardiac arrest. 
Effectiveness of vasopressin in catecholamine-resistant 
shock and cardiac arrest is due to the fact that it acts 
in an acidic environment, which exists in prolonged 
cardiac arrest, where epinephrine loses its potency.(18,19) 
American Heart Association recommends it for CPR of 
adults with shock- refractory ventricular fibrillation.(20) 
Some but not all clinical trials demonstrated improved 
haemodynamic variables and survival when using 
vasopressin as an alternative to epinephrine during 
resuscitation from cardiac arrest.  As a placebo- 
controlled trial has yet to be conducted and due to 
insufficient evidence, the European Resuscitation 
Council did not include vasopressin in the universal 
algorithm in its published guidelines and stated that 
“further evidence is required before this agent can be 
firmly recommended”.(21) 
 Anaphylaxis also presents as vasodilatory shock, 
as various case reports and series have shown a 
beneficial effect of using vasopressin in vasodilatory 
shock.(22,23) That was the reason we used vasopressin 
as a last resort following volume loading, use of 
adrenaline, noradrenaline and phenylephrine. No 
controlled trials of treatment in humans are currently 
available and recommendations for use of vasopressin 
for anaphylactic shock are based on case reports and 
summaries of experience. There are no guidelines 
regarding use and dosage of vasopressin in anaphylaxis 
refractory to adrenergic vasopressors. In different 
cases, report of anaphylaxis 2–5 units of vasopressin 
have been used.(16,24) We therefore decided to start 
with 2 units and then increase the dosage. The patient 
responded to 2 units of vasopressin, vascular tone was 
restored, and did not require further doses. 
 Based on our experience, we conclude that the 
complexity and severity of anaphylaxis are such that 
no single algorithm can adequately treat all cases. 
Currently, there is no guideline or algorithm for the 
management of anaphylaxis that includes the use 
of vasopressor other than epinephrine. Vasopressin 
should be considered early for catecholamine-
resistant anaphylactic shock and before resuscitation 
is discontinued. Guidelines for management of 
anaphylactic shock should also include vasopressin in 
association with pure alpha-agonist in acute circulatory 
shock due to anaphylaxis.
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